Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
InnoSkel awarded Innovation Passport by the UK MHRA for the treatment of a rare bone disorder First step in the recent UK MHRA initiative to accelerate the development and access to innovative...
-
Communiqué de presseNicox : Pré-sélection du premier patient en Chine dans l’étude de phase 3 Denali en cours sur le NCX 470 dans le glaucome Etude de phase 3 Denali co-financée à parts égales par...
-
Press ReleaseNicox Announces First Patient in China screened in the ongoing NCX 470 Denali Phase 3 Trial in Glaucoma Denali Phase 3 co-funded equally by Nicox and Ocumension TherapeuticsPhase 3...
-
HOUSTON, Dec. 15, 2021 (GLOBE NEWSWIRE) -- NFT platform Superfandom is launching a marketplace where superfans can buy access to future rare experiences with their favorite creators, both offline...
-
InnoSkel Appoints Dr Sophie Amsellem-Bosq as Chief Technical Officer Nice, France, 14 December 2021 – InnoSkel (the “Company”), a pioneering platform biotechnology company developing transformative...
-
Communiqué de presseNicox : Doug Hubatsch, nouveau Chief Scientific Officer, dirigera le développement clinique et non-clinique13 décembre 2021 – diffusion à 7h30 Sophia Antipolis, FranceNicox SA...
-
Press ReleaseNicox Appoints Doug Hubatsch as new Chief Scientific Officer to lead Clinical and Non-clinical DevelopmentDecember 13, 2021– release at 7:30 am CET Sophia Antipolis, FranceNicox SA...
-
-- Complete remissions with cytogenetic responses, hematologic improvement, and transfusion independence were observed in patients with previously untreated higher-risk MDS -- Objective responses...
-
Pressmeddelande Stockholm, 11 december, 2021 Immunicum presenterar Fas II-data som visar minskad MRD och förbättrad överlevnad med DCP-001-behandling hos AML-patienter på ASH 2021 Immunicum AB...
-
Press Release Stockholm, Sweden, December 11, 2021 Immunicum Presents Phase II Data Demonstrating Reduced MRD and Improved Survival with DCP-001 Treatment in AML Patients at ASH 2021 Immunicum AB...